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Background: Implementation science (IS) occupies a critical place
in HIV/AIDS research, reflected by a scientific track (“Track E”) at the
biannual International AIDS Conference. IS seeks to identify health
delivery strategies that cost-effectively translate the efficacy of
evidence-based interventions for HIV prevention, testing, and treat-
ment into impact on HIV incidence, quality of life, and mortality.
Method: We reviewed the content of Track E, and other
presentations relevant to IS, at the 22nd International AIDS
Conference held in Amsterdam in 2018. We identified key findings
and themes and made recommendations for areas where the field can
be strengthened by the 2020 meeting.
Results: Trials of “treat all” strategies in Africa showed mixed evidence
of effect. Innovations in HIV testing included expanding self-testing and
index testing, which are reaching groups, such as men, where previously
testing rates have been low. Adherence clubs and other innovations are
being trialed to improve retention in care, with mixed findings. The
implementation of pre-exposure prophylaxis for HIV prevention continues
but with many challenges remaining in identifying implementation
strategies that strengthen demand and support continuation.
Discussion: IS for HIV/AIDS treatment and prevention continues
to expand. IS for primary HIV prevention must be prioritized with a
dearth of rigorous, intersectoral studies in this area. The weakness of
routine data must be addressed. Costing and financing studies should
form a stronger component of the conference agenda. Implementa-
tion scientists must continue to grapple with the methodological
challenges posed by the real-world context for their research.
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INTRODUCTION
Implementation science (IS) studies examine ways to
deliver health-enhancing tools to those who need them rather
than evaluating the efficacy of the tools themselves. IS uses
frameworks, outcomes, and methodologies to analyze the
behavior of systems, organizations, groups, and individuals. It
seeks to close the gap between evidence and practice by
identifying delivery strategies that maximize the impact of
programs and health systems in the real world.1 In July 2018,
over 15,000 global HIV/AIDS researchers, programmers,
policy makers, and activists gathered at the AIDS 2018 in
Amsterdam to discuss the current state of the HIV pandemic.
“Track E” sought submissions on “innovations and advances
in implementation and service delivery and on best strategies
for the use of human, financial and other resources for
effective and equitable HIV and AIDS responses embedded
within broader public health and development frameworks.”
The arsenal of efficacious biomedical tools for HIV
prevention and treatment is larger than ever. For example,
research at the conference confirmed the high efficacy of
antiretroviral therapy (ART) in reducing onward HIV trans-
mission,2,3 providing supporting evidence for the UNAIDS
“U = U” campaign (“Undetectable = Untransmittable”). The
PARTNER-2 study demonstrated that over 8 years, among
783 gay male couples, no HIV-positive partner with an
undetectable viral load infected his HIV-negative partner
through 74,567 episodes of unprotected anal sex. Similarly,
results from the Prevenir study showed that those taking oral
pre-exposure prophylaxis (PrEP) during periods of risk are
effectively protected from HIV infection, with no break-
through HIV infections among 1435 participants taking
event-driven PrEP “on-demand.”4
However, these efficacious tools do not yet benefit all
those who need them. IS must close this gap. The importance of
this agenda was clear as the conference opened. Long-term,
sustainable financing and political will for the HIV/AIDS
response seems fragile, emphasizing the need for innovation in
efficient, impactful program delivery. The Lancet Commission
on “advancing global health and strengthening the AIDS
response” urged that implementation of the HIV/AIDS response
must be integrated with broader global health efforts,5 while at
the same time strengthening the delivery of HIV prevention, as
declines in new infections have stagnated.6
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We critically reviewed HIV/AIDS IS presented at IAS
2018, under 4 themes: the impact of “treat all” strategies in
Africa; innovation in delivering HIV testing services and
case-detection; implementation strategies to supporting reten-
tion in care and treatment; and, optimizing the delivery of
primary HIV prevention. We conclude with some thoughts on
next steps for the IS agenda as we approach the next
International AIDS Conference in 2020.
METHODS
The Track E program included 85 abstracts, including
39 oral abstracts. Materials relevant to Track E were also
featured in plenary and cross-track sessions. As the rapporteur
team for Track E at the conference, at least one author of this
article attended each Track E oral presentation, and we had
access to written abstracts, most slides, and video recordings.
We summarized the conference in real time over the week of
July 23–27, 2018, writing session summaries of all Track E
oral abstract sessions and many other sessions of relevance to
IS, 4 daily reports, and an oral presentation summarizing
findings across Track E.7 After the conference, we reviewed
these materials, agreed on key themes, and identified cross-
cutting issues. We summarize here the results from rigorous
IS studies presented at the conference, including impact
evaluations (with both randomized and nonrandomized
designs), process evaluations, economic evaluations, and
systematic reviews of program delivery strategies, regardless
of scale or geography. We refer to abstracts reported at the
conference and, in addition, refer to subsequently published
articles where these were available.
RESULTS
Of the 39 oral abstracts in Track E, 8 reported data from
nonrandomized evaluation studies, 7 reported data from
randomized trials, 6 reported case studies in a “Lessons
Learned” format, 5 reported costing or finance studies, 5
reported modeling studies, 4 reported data from principally
qualitative research, 2 reported routine data, 1 survey and 1
systematic review.
Theme 1: The Impact of “Treat All”
Implementation Strategies in Africa
Since 2015, the WHO has recommended a “treat all”
approach, where anyone confirmed as testing HIV positive
should begin antiretroviral treatment within 7 days, with the
offer of same day initiation, in response to evidence that
immediate initiation of ART keeps people alive, healthy, and
reduces the risk of transmitting the virus onward.8 This
strategy also means that delivery can be streamlined to be
more effective, compared with approaches that required pre-
ART follow-up to assess treatment eligibility by CD4 count
thresholds. In a cross-track session, 3 cluster randomized
trials, all of which launched before this the WHO recom-
mendation, released findings on the implementation and
impact of universal test and treat strategies in sub-Saharan
Africa. These trials were notable for their large size, and
although all 3 studies examined HIV incidence as the ultimate
outcome of interest, each examined a different implementa-
tion strategy to optimize uptake.
The “Ya Tsie” trial in Botswana reported a reduction in
HIV incidence of 31% associated with the delivery of a
combination HIV prevention program measured among a
cohort of nearly 9000 individuals from communities covering
about 10% of the national population.9,10 The intervention
included home-based and mobile testing and linkage-to-care
support, with treatment guidelines changing in both arms of
the trial over time toward a treat all approach. The
intervention generated a difference in the proportion of all
HIV-positive individuals virally suppressed on ART between
the arms of the trial. The SEARCH trial in Kenya and Uganda
implemented an intervention based on community health
fairs, where a “patient-centered multidisease model” was
delivered at baseline in intervention and control communities
and then over time in intervention communities only.11,12
Immediate ART was available throughout the trial in the
intervention arm, whereas in the comparison arm, guidelines
changed over time. The trial reported improvements in the
treatment cascade and reductions in TB and all-cause
mortality among both HIV-infected individuals (21% reduc-
tion) and all community residents (11% reduction) associated
with the intervention. However, there was no difference in
3-year cumulative HIV incidence between the trial arms in
cohorts of some 40,000 individuals. Finally, the MaxART
trial showed improved retention in care (86% retention at
12 months under intervention compared with 80% retention
with standard of care), with no increase in per-patient ART
delivery costs, during a stepped-wedge trial of the roll out of
facility-based immediate ART initiation in the kingdom of
Eswatini.13 Although not presented at this conference, the
results for HPTN 071 (PopART), another large, 3-arm
universal test–and-treat study conducted in Zambia and South
Africa, were subsequently published in July 2019.14 In this
trial, both treatment groups received door-to-door interven-
tions including HIV testing and other services. Compared
with the standard of care arm, HIV incidence was signifi-
cantly lower by 30% in the clusters that initiated treatment
according to country guidelines (which in the second-half of
the trial was immediate ART) but was only 7% lower
(nonsignificantly) in the clusters that initiated treatment
immediately from the start of the trial.
Theme 2: Innovations in Delivering HIV
Testing Services and Case Detection
In addition to the multicomponent “treat-all” trials, the
conference saw a range of presentations on innovations in
delivering HIV testing services and identifying HIV cases.
Engagement with HIV testing is a means to ensure early entry
into prevention and care. The Thai Red Cross, for example,
showed how HIV testing can not only link HIV-positive key
populations to treatment and care but can also be an effective
route to link those testing negative, but at risk to HIV
prevention services.15 They stressed the need for frequent and
regular testing for key populations to stay negative through
linkage and follow-up within the prevention program.
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Rates of HIV case detection and repeat HIV testing
remain lower among men than women in many settings,
particularly sub-Saharan Africa. Consequently, additional
HIV testing programs to reach men were shown to be cost-
effective (able to identify new cases of HIV at a cost of less
than approximately 500 USD per new diagnosis) in a range of
settings.16 In Malawi, male-targeted HIV testing events at
weekends in mobile clinics increased the proportion of men
tested from 69% in 2014 compared with 78% in 2017.17 HIV
self-testing also provides an important opportunity for
screening, by bringing HIV testing services to men. In Kenya,
the secondary distribution of 2 additional oral HIV self-test
kits by pregnant women aged 18–24 years attending antenatal
and postpartum care to their male partners had a large effect
on the proportion of these partners tested for HIV, with
approximately a 37% higher uptake of HIV testing in the
intervention compared with the control group.18 Rates of
couples testing were also higher in the intervention arm
(77.8% compared with 38.1%, respectively), as was disclo-
sure of HIV status to partners. In another study in Malawi,
community-based distribution of HIV self-tests increased
levels of HIV testing in the previous 12 months (68%
reported recently testing in the community-based distribution
of HIV self-testing kits arm versus 48% testing in the standard
of care arm) and had a particularly strong effect among men
(65% compared with 42%, respectively).19 However, despite
an increase in testing, there was little evidence that
community-based distribution of HIV self-testing kits had
an impact on ART initiations. Because HIV self-testing is a
first screening step and requires confirmatory testing accord-
ing (although many self-testers have previously tested) to the
Malawi national HIV diagnostic testing algorithm, ensuring
linkage to both confirmatory testing and ART for those who
test HIV positive is necessary to show effectiveness, and few
studies presented data on these critical outcomes, critically
among those who test negative on self-testing. Linkages to
prevention are as important to linkages to treatment among
those who test positive.
The conference also saw reports from programs actively
offering HIV tests to the social and/or sexual and/or drug-
injecting networks of index cases of HIV infection. One
experience was in Ukraine, where an “optimized case
finding” delivery model incentivized peer referrals for testing
by people testing positive and increased the yield of positive
tests from 3.4% to 23.6%.20
Theme 3: Implementation Strategies to
Support Retention in Care and Treatment
Once diagnosed, people living with HIV need to be
linked to care, offered and initiated on an appropriate ART
regimen, and then retained on treatment with a suppressed
viral load. This is a major challenge for service delivery,
especially in fragile and already overloaded health systems
and in contexts where poverty and stigma act as barriers.
In Mozambique, data from 10 years of peer support
groups involved in community ART distribution and mutual
psychosocial support including 2167 patients with HIV
attending 13 clinics (over the period from February 2008 to
October 2017) showed that 87.5% were retained in care and
76.4% remained in their group.21 In Zambia, an urban
adherence club model that provided off-hours facility access
and group-based drug distribution showed that these efforts
significantly reduced late drug collection at 7 and 28 days
over 12 months compared with standard of care in a
randomized trial.22 In Ethiopia, an approach to improve
adherence and reduce the burden on health facilities based
on appointment spacing had been increased to 6 months and
rapidly scaled up and was found to be acceptable by clients
and service providers,23 whereas in Tanzania, community-
based ART delivery through an existing cadre of home-based
carers was shown to be acceptable, feasible, and noninferior
to existing clinic-based models.24,25 Finally, an innovative
study from Vancouver among people who use drugs showed
that where HIV services were successfully integrated with
other health platforms, ART treatment success was facilitated
by supporting access to methadone maintenance therapy.26
Theme 4: Optimizing the Delivery of Primary
HIV Prevention Programs
Implementing HIV prevention programs poses unique
challenges and requires multisectoral collaborations to be
successful. A modeling study reported at the conference
showed that currently the most cost-effective primary pre-
vention tools (including condoms and voluntary medical male
circumcision) are funded at only 70% of need.27 PrEP
delivery and the challenges of implementation especially to
high-risk groups were a major theme of the conference.
One strategy to strengthen prevention is to improve the
use of data to better target efforts. In Kenya, the “prevention
roadmap” strategy uses modeled estimates of HIV incidence
to geographically segment Kenya into high-, medium-, and
low-intensity districts, and programming plans and resources
follow this. The PEPFAR DREAMS initiative for prevention
of HIV infection among adolescent girls and young women
also apply a geographic targeting step at its first stage, before
identifying and prioritizing the highest-risk young women for
service delivery. Each of these examples was described at the
conference, and we anticipate results on the impact of these
implementation efforts to be described at future conferences.
Data from Zimbabwe and Uganda were used to develop a
“prevention cascade” model to help guide prevention efforts
not just in terms of where and among whom to prioritize
action but what determinants of risk should be targeted.28–30
A number of studies examined PrEP programs. The
ACCESS study in Kenya and South Africa concluded that
self-perceived risk is an important driver of PrEP Initiation.31
The study also highlighted a number of missed opportunities
to offer PrEP in health facilities. In the PriYA study in Kenya,
22% of young women offered PrEP alongside contraception
services initiated it, and uptake was higher among those who
had known risk factors for HIV including an STI diagnosis, a
partner of unknown HIV status, and the experience of forced
sex or violence.32 As with the ACCESS study, reasons for
declining PrEP included low perceived risk and needing to
consult a partner. Across a range of studies, it was clear that
demand for PrEP needs to be strengthened through better
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messaging and methods for accurate self-assessment of risk,
integration with other services and other demand and supply
side interventions. Equally complex will be to identify
effective strategies to support PrEP continuation, which
unlike ART does not need to be lifelong but regularly taken
only during periods of risk. A Kenya demonstration project
among female sex workers showed significant drop offs in
continuation at 1, 3, and 6 months after initiation.33 The
EMPOWER study in South Africa and Tanzania showed
initial high uptake of PrEP among young women but
subsequent high rates of drop out over 12–15 months and
no impact of an adherence club intervention on rates of
continuation.34 Looking forward, potential future products
that are longer lasting and may incorporate pregnancy
prevention may be more effective and cost-effective in
high-risk populations in Africa.7
Finally, a small number of studies reported on broader
combination prevention approaches. A South African cluster-
randomized trial of a parenting intervention combining cash
with parenting skills had positive impacts on a number of the
psychosocial determinants of risk among adolescents.35 In
another small South African study, adolescent friendly
services saw greater uptake of both HIV testing and condoms
from adolescents attending these clinics.36 In Tanzania, a
cluster-randomized controlled trial reported a 10-session
participatory gender training curriculum delivered to women
taking part in a group-based microfinance loan scheme
reduced physical intimate partner violence by a third over a
2-year period.37
DISCUSSION
“Track E” at AIDS 2018 included an array of
implementation strategies to deliver HIV testing, prevention,
and treatment services and investigated outcomes ranging
from uptake of services to HIV incidence. Yet many
questions remain about how best to deliver and evaluate
programs in the real world. For example, there were few
studies among pediatric or adolescent populations, in human-
itarian settings, or that measured viral load among PLHIV.
We need to refocus IS on pragmatic approaches that may be
less costly, more timely, and provide insight to the program
delivery questions.
We highlight 4 areas where we hope to see progress by
the International AIDS Conference in 2020. First, we hope to
see more on strategies for delivery of primary HIV prevention
programs. Track E at AIDS 2018 was dominated by studies
on strengthening the treatment cascade. The same urgency
has not yet been applied to innovations in the delivery of
primary prevention. With stagnating financing and burgeon-
ing populations in many affected countries, the need for
treatment for growing numbers of people into the foreseeable
future is a widely recognized challenge. By contrast, although
we have a range of efficacious prevention tools for uninfected
individuals, both old (condoms) and new (voluntary medical
male circumcision and PrEP), prevention programs in many
settings are still grappling with how best to address demand
and supply side barriers so these methods can be optimally
scaled. Insofar as prevention has always been a harder sell
than treatment,38 the need for interdisciplinary learning on
human behavior is paramount. Research from sociology,
psychology, economics, and business can be used to drive
many aspects of consumer behavior through an understanding
of human social needs and desires, and we must continue to
innovate in the HIV response.
Second, economics and financing studies can be
strengthened. Costing, cost-effectiveness, and efficiency
studies of delivery strategies are essential, but remain rare.
Furthermore, there was little research on sustainable ap-
proaches to financing the epidemic response. A successful
HIV response that optimizes the full tool box of treatment and
prevention know-how requires accurate analyses of costs. We
do not yet have the economic evidence to understand where
and how constrained funds should be spent, and we are failing
to develop innovative and robust financing strategies for the
long term. Discussions about the place of HIV within broader
health system financing with a view to integrating the
delivery of HIV prevention, testing, and treatment services
with related communicable and noncommunicable diseases
were also missing. As people with HIV live longer, diseases
of aging will grow in importance, and with the push for
universal health coverage, expanding the focus may highlight
areas for improving health system efficiencies. Every dollar
spent on vertical HIV programs has an opportunity cost.
Where programs are not meeting their aims, resources might
be better spent elsewhere. This requires an unsparing eye and
the inclusion of process, implementation, and outcome
evaluations, including costing, as part of any program.
Third, the idea of data-driven programming was
common across the conference. However, there is space for
vast improvements in routine data systems. The possibilities
for IS would be expanded by robust, routine programmatic
data systems, including individual identifiers that permit
programs to evaluate individual clinical outcomes, and with
the ability to course correct for greater impact or efficiency,
including better tracking of clinic visits and procedures. At
AIDS 2018, it was clear that sufficient investment, co-
ordination, analysis, and harmonization across a myriad of
sources of individual data are yet to happen. Rarely are
routine HIV data systems sufficient to support rigorous IS.
For example, lack of reported repeat viral load tests restricted
an assessment of community adherence groups on viral
suppression in Mozambique21; poor follow-up and missing
data limited the ability to assess program quality in commu-
nity health worker program to trace lost patients in Bot-
swana39 and in a program to assess the impact of same day
diagnosis and treatment on retention of children in care in
Uganda.40 Systems that integrate and securely store unique,
universal, health identifiers, and/or identifiable information to
facilitate linkage can track patients within and across
programs and provide deduplicated individual-level strategic
information. Because HIV services are mainstreamed and
integrated with other global health efforts, strengthened data
systems that form the backbone for supporting and assessing
patient care, prevention, and intelligent programming
are essential.
Finally, implementation scientists face methodological
challenges in undertaking their work and must continue to
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innovate. Insofar as IS focuses on real-world, pragmatic
research, we have less control over the context of IS research
compared with research in basic and clinical science. For
example, major changes in international guidelines regarding
ART provision were rolled out during the conduct of the
implementation trials of universal test–and-treat strategies. As
is the case in prevention and clinical science, ethical issues
mean that true control groups sometimes cannot be justified,
and yet there remains a critical need to develop and refine
implementation strategies. The increase in interdisciplinary
research, including process evaluations that give rise to
understanding of mechanisms of action and potential trans-
ferability and scalability of implementation strategies, is
encouraging. In addition, we must pursue efficient evaluation
methods that obtain high-quality data at a lower cost.
Hybrid designs offer one potential method requiring further
investigation.41 We may also choose to pursue a greater
focus on evaluations powered on implementation (eg,
coverage and uptake), process, and short-term mediating
outcomes, recognizing that it is also incumbent to pre-
specify and report these outcomes in trials powered to
detect effectiveness. This methodological innovation must
continue and gather pace to support the critical IS effort
and, thus, the translation of efficacious tools and methods
for HIV prevention and treatment into population impact
and, ultimately, epidemic control.
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